Page last updated: 2024-08-24

aripiprazole and Mouth Neoplasms

aripiprazole has been researched along with Mouth Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Jiang, C; Kim, HS; Kim, JR; Lee, JS; Lee, SH; Park, JH; Park, JW; Yoon, S	1

Other Studies

1 other study(ies) available for aripiprazole and Mouth Neoplasms

Article	Year
A Low Dose of Aripiprazole Has the Strongest Sensitization Effect Among 19 Repositioned Bipolar Drugs in P-gp-overexpressing Drug-resistant Cancer Cells. Anticancer research, 2021, Volume: 41, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Apoptosis; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Repositioning; Drug Resistance, Neoplasm; Furans; G2 Phase Cell Cycle Checkpoints; Humans; Ketones; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck; Vincristine	2021

Article

Year

A Low Dose of Aripiprazole Has the Strongest Sensitization Effect Among 19 Repositioned Bipolar Drugs in P-gp-overexpressing Drug-resistant Cancer Cells.

Anticancer research, 2021, Volume: 41, Issue:2

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Apoptosis; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Repositioning; Drug Resistance, Neoplasm; Furans; G2 Phase Cell Cycle Checkpoints; Humans; Ketones; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck; Vincristine

2021